Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Exagen (XGN) Shares Outstanding (Weighted Average) (2018 - 2026)

Exagen filings provide 9 years of Shares Outstanding (Weighted Average) readings, the most recent being $131.0 for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 99.99% to $131.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $131.0, a 99.99% decrease, with the full-year FY2025 number at $819356.0, down 95.5% from a year prior.
  • Shares Outstanding (Weighted Average) hit $131.0 in Q1 2026 for Exagen, down from $819356.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $18.2 million in Q4 2024 to a low of $131.0 in Q1 2026.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $1.4 million (2025), compared with a mean of $7.9 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 1343.65% in 2023 and later plummeted 99.99% in 2026.
  • Exagen's Shares Outstanding (Weighted Average) stood at $17.1 million in 2022, then grew by 3.5% to $17.7 million in 2023, then rose by 2.96% to $18.2 million in 2024, then crashed by 95.5% to $819356.0 in 2025, then tumbled by 99.98% to $131.0 in 2026.
  • The last three reported values for Shares Outstanding (Weighted Average) were $131.0 (Q1 2026), $819356.0 (Q4 2025), and $1.4 million (Q3 2025) per Business Quant data.